ACADIA Pharmaceuticals Q2 2026 Earnings Report

ACADIA Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.05
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ACADIA Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $295.83 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ACADIA Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 4:30PM ET

ACADIA Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S. Food and Drug Administration approval for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Beyond NUPLAZID, ACADIA is pursuing additional indications for pimavanserin in dementia-related psychosis and Alzheimer’s disease psychosis, as well as exploring novel candidates for schizophrenia and other neuropsychiatric disorders. These efforts are complemented by strategic collaborations, translational research initiatives, and robust clinical trial programs to expand the company’s impact on patient care.

ACADIA serves patients and healthcare providers primarily in North America, with ongoing clinical studies and regulatory submissions extending into Europe and Asia-Pacific regions. The company leverages partnerships with academic institutions and industry collaborators to accelerate development timelines and enhance its global footprint. Guided by a leadership team with extensive experience in CNS drug development, ACADIA continues to build on its scientific heritage and commitment to delivering differentiated therapies for complex neurological conditions.